December 11 - 15, 2015
JN Biosciences presented the data showing the potent agonist activity of the proprietary anti-OX40 MultYbody™ for activation of human T cells at the Antibody Engineering and Therapeutics Meeting in San Diego, CA (click here for the poster).
May 2 - 6, 2015
Dr. Andrew Adams' group of Emory University presented the therapeutic efficacy of HuABC2, a humanized anti-CD122 IgG antibody, for prevention of renal allograft rejection in non-human primates and the efficacy of ChMBC7, a rat-mouse chimeric anti-mouse CD122 IgG antibody, in the mouse model of skin allograft rejection (click here for the abstract).
February 10, 2015
A U.S. patent (9028830) was issued for JN Biosciences' humanized anti-CD122 IgG antibody HuABC2, which has been developed for treatment of autoimmune disease and allograft rejection.
May 20, 2013
A U.S. patent (8952134) was issued for the MultYmab™ antibody engineering technology, which JN Biosciences has been using to generate potent agonist antibodies against immune constimulatory molecules for immunotherapy and death receptors for treatment of cancer.
May 18 - 22, 2013
A positive result of monotherapy with HuABC2, a humanized anti-CD122 IgG antibody, for treatment of renal allograft rejection in non-human primates was orally presented at the American Transplant Congress in Seattle, WA (click here for the abstract).
June 20, 2012
JN Biosciences presented the result of the monkey PK/PD/safety study of HuABC2, a humanized anti-CD122 IgG antibody, at the FOCIS 2012 Annual Meeting in Vancouver, Canada (click here for the poster).
